BioMed Research International / 2013 / Article / Tab 2 / Review Article
The Treatment Outcome and Radiation-Induced Toxicity for Patients with Head and Neck Carcinoma in the IMRT Era: A Systematic Review with Dosimetric and Clinical Parameters Table 2 Published studies with either IMRT or conventional techniques. Data included concomitant chemotherapy or not, follow-up, and radiation-induced toxicity.
Study Radiation treatment
Concurrent chemotherapy No. of patients (%)
Median followup (range) Toxicity (≥GrII)
Mean parotid- gland dose Mucositis Xerostomia Acute Late Acute Late Studer et al. [24 ]† IMRT Yes (86%) 16 mths (4–44 mths) 65% — — —
Lee et al. [8 ] IMRT Yes 31 mths (20–64 mths) 66% — 66% 12% 2DRT Yes 46 mths (3–93 mths) 72% 65% 67% Garden et al. [25 ] IMRT Yes (8%) 45 mths (15–63 mths) — — — — 23.9 Gy Daly et al. [26 ]† IMRT Yes (87%) 29 mths (4–105 mths) 93% — — — 33.2 Gy Chao et al. [27 ]† IMRT Yes (23%) 33 mths (9–60 mths) 86% — — 12% 18.6 Gy Huang et al. [28 ] IMRT Yes 33 mths (3–72 mths) 92% — — 34% 25.5 Gy Setton et al. [29 ]† IMRT Yes (88%) 36.8 mths (3–135 mths) 68% — 28% 29% 25.8 Gy Kwong et al. [34 ] IMRT No 24 mths (11–42 mths) 82% — — 40% (1yrs) 15% (2yrs) 38.8 Gy Wolden et al. [35 ] IMRT Yes (93%) 35 mths (3–74 mths) 32% (1yrs) 35.2 Gy
Kam et al. [36 ] IMRT Yes (30%) 29 mths (8–45 mths) 92% 75% 23% (2yrs) 39 Gy 16.7% (2yrs) 31 Gy Lee et al. [38 ] IMRT Yes (65%) 31 mths (6–55 mths) — 22% — 33% Lee et al. [40 ] IMRT Yes (75%) 31 mths (7–72 mths) 94% — 58% Liu et al. [41 ] IMRT Yes (58%) 13.0 mths (8–18 mths) — 79% — 53% 37.8 Gy Luo et al. [42 ] 3D-CRT No 58 mths (25–92 mths) 74% 12% 12% 52.8 Gy Al-Mamgani et al. [47 ] IMRT + 3D-CRT Yes(28.3%) 32 mths (7–172 mths) 14.1% 23.6 Gy Lee et al. [50 ] IMRT Yes (65%) 26 mths (17–58 mths) 48% 3.2% 26 Gy Van Gestel et al. [51 ]† IMRT Yes Def: 63% Post: 23% 18.7 mths (0.13–51.7 mths) 100% 44% Peponi et al. [52 ]† IMRT Yes (85%) 55 mths Obj: 7.3 % Sub: 3.6%
Gupta et al. [23 ] 3D-CRT Yes 40 mths (26–50 mths) 93% 53 Gy IMRT Yes (90%) 40 mths (26–50 mths) 77% 34.3 Gy
Lambrecht et al. [18 ] 3D-CRT Yes (80%) 68 mths (37.2–104 mths) 44% 68% 53 Gy IMRT Yes (81%) 35 mths (4.7–63.5 mths) 32% 23% 34 Gy Toledano et al. [53 ]† IMRT Yes (37.5%) 25.3 mths (0.4–72 mths) ~73% — — ~58%
Clavel et al. [9 ] IMRT Yes 42 mths 75% 8% (2yrs) 2-3DRT Yes 42 mths 77% 74% (2yrs)
Vergeer et al. [20 ]† IMRT Yes (43%) — 32% (6 mths) 27 Gy 3D-CRT Yes (35%) — 56% (6 mths) 43 Gy
Chen et al. [21 ]* IMRT Yes (9%) 44 mths 87% 36% 3D-CRT Yes (2%) 44 mths 89% 82%
Nutting et al. [12 ]† IMRT Yes (43%) 44 mths 93% 71% 69% 36.5 Gy 3D-CRT Yes (40%) 44 mths 94% 91% 76% 61 Gy Wong et al. [33 ] IMRT Yes (70%) 34 mths (9–50 mths) 67.4% 2.3% 30 Gy Sultanem et al. [44 ] IMRT Yes (91%) 21.8 mths (5–49 mths) 97% 28% Su et al. [45 ] IMRT No 50.9 mths (12–104 mths) 73% 36% 15.4% (1yrs) 9.0% (2yrs) 31 Gy Wang et al. [43 ] IMRT Yes (83%) 47.1 mths (11–68 mths) 33.3% 4.7% 12.3% (2yrs) 27.6 Gy
Rades et al. [22 ]* 2DRT Yes (8%) ~90% 73% 3D-CRT Yes (23%) ~90% 63% IMRT Yes (6%) ~90% 17%
Tham et al. [39 ] IMRT Yes 36.5 mths 29% (Gr3) 3% (Gr3) IMRT No 36.5 mths 20% (Gr3) Kim et al. [46 ] 3D-CRT No 48 mths 57% 19% De Arruda et al. [32 ]† IMRT Yes (86%) 18 mths (8.4–76 mths) 92% 60% 33% 26.5 Gy
Postoperative RT; † definitive and postoperative RT; all the rest: definitive RT.